In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2023 ASCO Annual Meeting in ovarian cancer, uterine cancer, cervical cancer, multiple myeloma, and head and neck cancer.
Cancer survivor Bill Brummel shares what it was like receiving an oropharyngeal cancer diagnosis, why he needed to receive a laryngectomy many years later, how the surgery impacted his self-image, and how he regained his confidence after the operation.
Cancer survivor Eva Grayzel shares what it was like preparing for cancer treatment and the things that helped her endure treatment both physically and emotionally.
In this post, Dr. Cristina Rodriguez and Dr. Natalie Uy describe what to know about caring for a loved one with advanced head and neck cancer toward the end of life, including the challenges unique to people with this type of cancer and how to get help.
In this podcast, 3 Cancer.Net Associate Editors discuss new research presented at the 2022 ASCO Annual Meeting in head and neck cancer, brain tumors, and health equity.
Read research from the April 2022 session of the ASCO Plenary Series, which highlights a clinical trial that studied a medication called tislelizumab combined with chemotherapy to treat recurrent or metastatic nasopharyngeal cancer.
Dr. Kedar Kirtane and Dr. Perrin Romine discuss the common sexual health concerns people with head and neck cancer have and how to get help with these concerns during and after cancer.
In this podcast, Dr. Kedar Kirtane discusses research from the 2022 Multidisciplinary Head and Neck Cancers Symposium, including discussions around cancer disparities in head and neck cancer, treatment for HPV-positive oropharyngeal cancer, and strategies for treating HPV-related head and neck cancers.
The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.
Oral cancer survivor Eva Grayzel shares how her diagnosis gave her a new appreciation for words and how she changed the language she uses to embrace positivity after her voice returned.
